Premium
Serum amyloid A in equine health and disease
Author(s) -
WitkowskaPiłaszewicz O. D.,
Żmigrodzka M.,
Winnicka A.,
Miśkiewicz A.,
Strzelec K.,
Cywińska A.
Publication year - 2019
Publication title -
equine veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.82
H-Index - 87
eISSN - 2042-3306
pISSN - 0425-1644
DOI - 10.1111/evj.13062
Subject(s) - serum amyloid a , subclinical infection , acute phase protein , medicine , biomarker , horse , inflammation , disease , physiology , serum amyloid a protein , immunology , biology , paleontology , biochemistry
Summary Serum amyloid A (SAA) is the major acute phase protein in horses. It is produced during the acute phase response (APR), a nonspecific systemic reaction to any type of tissue injury. In the blood of healthy horses, SAA concentration is very low, but it increases dramatically with inflammation. Due to the short half‐life of SAA, changes in its concentration in blood closely reflect the onset of inflammation and, therefore, measurement of SAA useful in the diagnosis and monitoring of disease and response to treatment. Increases in SAA concentration have been described in equine digestive, reproductive and respiratory diseases and following surgical procedures. Moreover, SAA has proven useful for detection of some subclinical pathologies that can disturb training and competing in equine athletes. Increasing availability of diagnostic tests for both laboratory and field use adds to SAA's applicability as a reliable indicator of horses’ health status. This review article presents the current information on changes in SAA concentrations in the blood of healthy and diseased horses, focussing on clinical application of this biomarker.